Cooley advised Opthea, a biopharmaceutical company focused on therapies for progressive retinal diseases, on its $128 million initial public offering of 8,563,300 American Depository Shares. The underwriters have the option to purchase up to an additional 1,425,000 shares. Partners Ferish Patel, Div Gupta, John McKenna and Brent Siler led the global Cooley team advising Opthea.